



Research, Advances, Challenges and Perspectives in the Development of Vaccines against Dengue, Zika and Chikungunya Viruses

Guest Editors:

Dr. Wildriss Viranaicken
wildriss.viranaicken@univ-reunion.fr

Dr. Pascale Krejbich
pascale.krebich@univ-reunion.fr

Deadline for manuscript
submissions:

31 December 2020

Message from the Guest Editors

To establish vaccines, it is necessary to define the host-pathogen interaction mechanisms and especially the molecular determinants of virulence. Among the challenges, it is necessary to consider the existence of the ADE phenomenon, a possible co-circulation of two or more of these viruses in endemic areas and the high prevalence of Guillain-Barré syndromes during some of these viral infections. A candidate vaccine must therefore be able to avoid inducing this type of response in humans and must be able to be used by the most vulnerable populations in endemic areas such as newborns or pregnant women. The purpose of this Special Issue “Research, advances, challenges and perspectives in the development of vaccines against Dengue, Zika and Chikungunya viruses” is to present the latest research results that advance our knowledge on the progress conception of vaccine strategies against these arboviruses. It is open to the submission of manuscripts, reviews, research, short communications, hypothesis, perspectives and point of view, that describe research or idea that can improve our knowledge on this issue for vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access:—free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: Indexed in the **Science Citation Index Expanded (SCIE)** and BIOSIS Previews in Web of Science and in Scopus. Citations available in PubMed, full-text archived in **PubMed Central**.

CiteScore (2019 Scopus data): **4.5**, which equals rank 92/283 (Q2) in the category 'Infectious Diseases', rank 116/200 (Q3) in 'Immunology' and rank 109/301 (Q2) in 'Pharmacology', among others.

Contact Us

Vaccines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com